Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Comparison of the Additivity of Brinzolamide Ophthalmic Suspension, 1% (Azopt) and Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan P) to Travoprost Ophthalmic Solution, 0.004% (Travatan) in Patients With Elevated IOP on Travoprost. A Three Month Double-Masked, Multi-Center Trial in the United States

NCT00121147 is registered in ClinicalTrials.gov with Hermann Eye Center as lead sponsor.

NCT NCT00121147
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00121147 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Comparison of the Additivity of Brinzolamide Ophthalmic Suspension, 1% (Azopt) and Brimonidine Tartrate Ophthalmic Solution, 0.15% (Alphagan P) to Travoprost Ophthalmic Solution, 0.004% (Travatan) in Patients With Elevated IOP on Travoprost. A Three Month Double-Masked, Multi-Center Trial in the United States
Lead sponsor
Hermann Eye Center
Phase
Not applicable
Overall status
Completed
Start date
September 30, 2003
Completion date
October 31, 2005
Enrollment
200
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

ocular hypertension, open angle glaucoma, pseudoexfoliation syndrome